[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"perennial-allergic-rhinitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:perennial-allergic-rhinitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,70,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100404318","the-role-of-the-nasal-allergen-provocation-test-in-starting-and-monitoring-allergen-immunotherapy-100404318",false,"NCT04544774","The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy","The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy: An Academic Multicentre Clinical Study","Inclusion Criteria:\n\n* Age \\>18 and ≤60 years\n* Persistent or intermittent allergic rhinitis complaints, confirmed by SPT and\u002Fof immunocap for the specific IgEs.\n\nOR suspected local allergic rhinitis\n\n* Patients who start with AIT treatment\n* The patient must be motivated and willing to come to all visits\n* The patient must be able to understand and sign the informed consent\n\nExclusion Criteria:\n\n* Uncontrolled asthma\n* Conditions affecting the functioning of the immune system (eg: immune deficiencies, malignancies, autoimmune diseases)\n* Use of β-blockers, immunosuppressants or ACE inhibitors\n* Hypersensitivity to aluminum hydroxide and\u002For hypersensitivity to any of the excipients in AIT\n* Anaphylaxis after allergen challenge in the past\n* Acute rhinosinusitis in the last 12 weeks\n* Recent surgery on the nose and\u002For paranasal sinuses in the last 12 weeks\n* Pregnancy","ALL","18 Years","60 Years",{"count":20,"type":21},200,"ESTIMATED","3 Years","OBSERVATIONAL","This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy.\n\nThe NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years.\n\nThis study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine \u002F Allergology",[26,27,28],"Perennial Allergic Rhinitis","Seasonal Allergic Rhinitis","Local Allergic Rhinitis","RECRUITING","2026-04-30",{"date":32,"type":33},"2026-05-01","ACTUAL",{"date":35,"type":33},"2020-07-16",{"date":37,"type":21},"2026-12",{"name":39,"class":40},"Universitaire Ziekenhuizen KU Leuven","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100628270","phase-2-trial-of-jyb1904-injection-in-patients-with-perennial-allergic-rhinitis-100628270","NCT07459452","Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection Combined With Background Therapy in Patients With Perennial Allergic Rhinitis","Inclusion Criteria:\n\n1. Adult participants ≥18 years and ≤65 years of age at the time of signing the informed consent form (ICF).\n2. Physician-diagnosed PAR at screening, symptoms of allergic rhinitis present for a minimum of 2 years.\n3. Participants must have been on stable treatment with intranasal corticosteroids (INCS), with or without other background medications for at least four consecutive weeks before randomization, and rTNSS≥6 at screening.\n4. Within 1 year prior to screening or at screening, participants must have positive indoor allergen SPT and\u002For positive antigen-specific serum IgE to indoor allergens . Participants must have clinical symptoms associated with perennial allergen positivity (assessed by SPT) or positive serum antigen-specific IgE at study entry .\n5. A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.\n6. Participants who have concomitant asthma must use permitted regular asthma treatment during the study and have been stable in the 3 months prior to screening.\n7. Is willing and able to comply with daily eDiary.\n8. Participants must complete the eDiary during the baseline evaluation period (2 weeks prior to randomization) and meet the following criteria: (1) complete the eDiary for at least 4 days per week; and (2) rTNSS score ≥6 at randomization (average of Day-7 to Day-1).\n\nExclusion Criteria:\n\n1. Is currently on AIT subcutaneous immunotherapy or sublingual immunotherapy.\n2. Have received treatment with any rescue medication or adjustment to background therapy medications during the baseline evaluation period.\n3. Prior intolerance or inadequate response to omalizumab.\n4. Contraindications or hypersensitivity to antihistamines or intranasal corticosteroids, or history of anaphylaxis.\n5. Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 2-week baseline evaluation period and the 24-week double-blind induction period.\n6. Anticipates significant changes in their daily environmental exposure during the 2-week baseline evaluation period and the 24-week double-blind induction period.\n7. Has a history of nasal polyps or nasal polyps present at screening, moderate-to-severe nasal septum deviation, or rhinitis secondary to other causes.\n8. Has a known history of recurrent acute or chronic sinusitis.","65 Years",{"count":51,"type":21},135,"INTERVENTIONAL",[54],"PHASE2","This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.",[26],[58],"PAR","NOT_YET_RECRUITING","2026-03-05",{"date":62,"type":33},"2026-03-09",{"date":64,"type":21},"2026-04",{"date":66,"type":21},"2028-10",{"name":68,"class":69},"Jemincare","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":52,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":95},"100605049","investigation-of-the-effects-of-a-multispecies-probiotic-formulation-on-perennial-allergic-rhinitis-100605049","NCT07157462","Investigation of the Effects of a Multispecies Probiotic Formulation on Perennial Allergic Rhinitis","AllerGo","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Willing and able to provide informed consent in French\n* Persistent perennial allergic rhinitis induced by a least one perennial allergen in the last two years.\n* Positive skin prick test ≥5 mm for any of the following allergens: cat, dog and mites\n* Mean global score of miniRQLQ ≥ 2\n* TSS score of at least 7\n* Willing to discontinue consumption of fermented foods, probiotics (e.g., yogurts with live, active cultures or supplements), prebiotics or immune-enhancing supplements (e.g., Echinacea or fish oil).\n* Agreement on not starting new medication during the intervention (rescue medication excepted)\n* Women of childbearing potential with a negative pregnancy test throughout the study period and highly effective contraception: oral contraceptives, condom with spermicide, intrauterine device, bilateral tubal ligation, vasectomized partner\n\nExclusion Criteria:\n\n* Non-allergic rhinitis\n* Use of any prohibited medication (any systemic corticosteroids, androgens such as testosterone, or high doses of anti-inflammatory drugs: i.e., aspirin in doses 600 mg\u002Fd regularly) at the time of enrolment\n* Use of other probiotics-containing and prebiotics-containing products during the intervention period and 4 weeks before study start\n* Use of any antibiotics 6 weeks before randomization\n* Nasal polyposis\n* Currently enrolled in another intervention study (except observational studies)\n* Critically or terminally ill or admitted to the ICU\n* Had received chemotherapy or other immune-suppressing therapy within the previous year.\n* Other conditions that according to the investigator might interfere with the evaluation of the study objectives\n* Patients being treated for or had any of the following physician-diagnosed diseases or conditions: HIV; immune modulating diseases (autoimmune disease, hepatitis, cancer, etc.); kidney disease; pancreatitis; pulmonary disease; hepatic or biliary disease; or gastrointestinal diseases or conditions, such as diverticulitis, ulcerative colitis, Crohn's disease, Celiac disease, short bowel disease, ileostomy, or colostomy, but not including gastroesophageal reflux disease,\n* Subjects with a low compliance rate (appreciated by the investigator) during the run-in period",{"count":78,"type":21},98,[80],"NA","The goal of this clinical trial is to learn if a probiotic formulation consisting of multiple bacterial strains has a positive effect on the quality of life of participants with chronic perennial allergic rhinitis symptoms. The researchers will also study whether the probiotic formulation influences the symptoms of allergic rhinitis. Participants with allergies to house dust mite, cats and\u002For dogs will be included in the study.\n\nThe main questions it aims to answer are:\n\nDoes the probiotic formulation have an impact of the quality of life of the participants? Does the probiotic formaluation have an effect on the severity of the symptoms of allergic rhinitis? Are there differences in the effects depending on the allergies the participants have?\n\nResearchers will compare the probiotic formulation to a placebo (a substance that contains no probiotic bacteria but looks, smells, and tastes the same) to see if the probiotic formulation improves the quality of life of participants with chronic allergic rhinitis. In addition, also a GI symptom questionnaire will be filled in by the participants weekly\n\nParticipants will visit the clinic for the screening, and at the start, and at the end of the intervention for checkups and sampling. During the intervention they will take the probiotic formulation or a placebo twice every day for 12 weeks. They will keep a diary of their symptoms and note whenever they use anti-histamines and every two weeks they will fill in a questionnaire about their quality of life.",[26],[84,85,86],"Multispecies probiotic","House dust mite allergy","cat and dog allergy","2025-11-18",{"date":89,"type":33},"2025-11-24",{"date":91,"type":33},"2025-09-01",{"date":64,"type":21},{"name":94,"class":69},"Winclove B.V.",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":16,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":52,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":95},"100610767","phase-1-bioequivalence-study-of-aju-r713-and-r713r-in-healthy-adult-volunteers-100610767","NCT07231861","Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-R713\" and \"R713R\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adults aged 19 years or older at the time of screening.\n* Body mass index (BMI) between 18 and 30 kg\u002Fm².\n\n  * Male subjects: body weight ≥ 50 kg.\n  * Female subjects: body weight ≥ 45 kg.\n* Clinically healthy based on medical history, physical examination, vital signs, electrocardiogram (ECG), and laboratory test results, as determined by the investigator.\n* Willing and able to provide written informed consent after receiving a full explanation of the study.\n* Subjects (and their partners, if applicable) agree to use highly effective, non-hormonal contraception from the first dosing day until one week after the last dose.\n\nExclusion Criteria:\n\n* Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.\n* Participation in any clinical trial involving investigational products within 6 months prior to the first dose.\n* Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.\n* History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).\n* Known hypersensitivity to the investigational product or its components.\n* Known metabolic or genetic disorders such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption, or phenylketonuria.\n* History of clinically significant psychiatric illness.\n* Pregnant or breastfeeding women, or women with a possibility of pregnancy.",true,"19 Years",{"count":106,"type":21},60,[108],"PHASE1","To Evaluate the Safety and Pharmacokinetics of Pranlukast hydrate in Healthy Adults.",[111,26],"Bronchial Asthma","2025-11-16",{"date":114,"type":33},"2025-11-19",{"date":116,"type":21},"2025-12",{"date":116,"type":21},{"name":119,"class":69},"AJU Pharm Co., Ltd."]